tbuckley/cabot-search huggingface dataset:
Brain pH Response to Hyperventilation in Panic Disorder: Preliminary Evidence for Altered Acid-Base Regulation
Authors: Seth D Friedman, C Mark Mathis, Cecil Hayes, Perry Renshaw, Stephen R Dager
Journal: American Journal of Psychiatry (2006)

Previous findings of excess brain lactate and delayed end-tidal CO(2) (pCO(2)) recovery in subjects with panic disorder during hyperventilation suggested altered acid-base regulation. Two models were posited to explain these results: 1) subjects with panic disorder demonstrate greater alkalosis to hyperventilation, implicating increased lactate as directly compensatory, or 2) subjects with panic disorder demonstrate reduced or blunted alkalosis, implicating increased lactate as overly compensatory to a normal pH response. In both models, delayed pCO(2) recovery in subjects with panic disorder could reflect slower pH normalization in the recovery phase.Asymptomatic medicated patients with panic disorder were studied during regulated hyperventilation. Phosphorous spectroscopy was used to measure brain pH every 2 minutes. Nine subjects with panic disorder were compared to 11 healthy subjects at baseline (five scans), during regulated hyperventilation (five scans), and across recovery (10 scans). Anxiety symptoms were assessed with standard ratings.No subject had a panic attack before hyperventilation. Subjects with panic disorder had lower pCO(2) during hyperventilation and slower pCO(2) recovery across the posthyperventilation interval. Despite this different respiratory response in the panic disorder group, brain pH increases were not significantly greater during hyperventilation, nor was pH return to baseline slowed during posthyperventilation. A linear regression model derived from data of healthy subjects showed pH blunting in the panic disorder group.Although subjects with panic disorder had greater hypocapnea during hyperventilation, their observed pH response, not altered from comparison levels, implicated exaggerated buffering. It is suggested that increased lactate could account for these findings.
Rocky Mountain Medical Association.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The nitty-gritty of pollution
Authors: H. F. Howe
Journal: JAMA (1970)

"Mr. Chairman, I rise as a representative of 1,800 shares of XYZ Electric Power Company, to protest this corporation's irresponsible chemical pollution of the air, water, and health of our region. We intend to advise consumers to withhold payment on their electric power bills until the corporation corrects this monstrous fouling of our lovely city! We also demand suspension of plans for that new nuclear plant which will fill our air and water with ionizing radiation and kill all the fish in the bay with thermal pollution!" The annual-meeting airing of such emotional reactions to environmental problems presents dilemmas to thousands of companies, and indeed to thousands of urban governments in the decade of Aquarius. Among these dilemmas are (1) a scientific community caught short with insufficient information about the actual and relative hazards of prolonged exposure of the population to small doses of potentially toxic agents, (2) an exploding
A7.07 Phosphatidylinositol 3–kinase delta pathway a novel therapeutic target for sjoegren's syndrome
Authors: S Nayar, J Campos, CD Buckley, RA Allen, WA Fahy, A Payne, F Barone
Journal: Annals of the Rheumatic Diseases (2016)

<h3></h3> Sjögren’s syndrome (SS) is a chronic autoimmune disease characterised by B-cell hyper-activation and exocrine gland infiltration that results in loss of glandular function, systemic manifestations and autoantibody production. The phosphatidylinositol 3–kinase delta isoform (PI3Kδ) belongs to a family of intracellular lipid kinases that regulate metabolism, survival, proliferation, apoptosis, growth, and cell migration and has been successfully targeted in B-cell malignancies. Given the central role of the B-cells in the pathogenesis of SS we investigated evidence for the engagement of the PI3Kδ pathway in SS and the functional consequences of blocking PI3Kδ in an animal model of SS. PI3K pathway activation was investigated in salivary gland (SG) biopsies from patients with SS or non-specific chronic sialoadenitis (NSCS). Samples were stained for phosphorylated ribosomal protein S6 (pS6), a downstream effector in the PI3Kδ pathway. UCB5857, a small molecule inhibitor of PI3Kδ, was used either prophylactically or therapeutically <i>in vivo </i>in an inducible model of ectopic lymphoneogenesis in murine SGs that mimics SS. Flow cytometry, immunofluorescence and quantitative PCR was used on the murine isolated SG to evaluate the samples at peak of inflammation which is day 15 post-cannulation. Histological staining for pS6 showed significant expression of pS6 in SS samples relative to NSCS control, confirming engagement of the PI3K pathway. pS6 was detected within lymphoid aggregates in both T- and B-cell areas and on the periphery of the lymphoid foci in SG biopsies. pS6 staining was predominantly found on CD138<sup>+</sup> plasma cells in SG biopsies. Mice treated either prophylactically or therapeutically with UCB5857 displayed decreased lymphocyte infiltration in cannulated salivary glands relative to vehicle treated mice. Additionally, a gene expression profile associated with ectopic lymphoneogenesis (CXCL13, CCL19, CCL21) was significantly impaired in mice treated with UCB5857. Lymphoid aggregates in these mice were characterised by decrease in focus score, smaller size and reduced T/B-cell follicular organisation. Preliminary data implicates activation of PI3Kδ pathway in several cells within the SGs of SS patients that may contribute towards pathology. Accordingly, prophylactic and therapeutic blocking of PI3Kδ results in disaggregation of the inflammatory foci and resolution of SG inflammation in an animal model of SS.
Mental Retardation: Method of Diagnosis and Some Recently Described Syndromes
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A POUND OF PREVENTION
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.
Authors: Alvaro Moreno-Aspitia, Eileen McCormick Holmes, Christian Jackisch, Evandro De Azambuja, Frances M. Boyle, David W. Hillman, Larissa A. Korde, Debora Fumagalli, Miguel A. Izquierdo, Ann E. McCullough, Antonio C. Wolff, Kathleen I. Pritchard, Michael Untch, Istvan Lang, Binghe Xu, Ian E. Smith, Carlos H. Barrios, Richard D. Gelber, Jose Baselga, Martine J. Piccart-Gebhart
Journal: Journal of Clinical Oncology (2017)

502 Background: Pre-specified 5-year analyses of the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial defined in Amendments 11&amp;12. Methods: From June 2007 to July 2011, 8381 patients (pts) were randomised from 946 sites in 44 countries to receive either L+T, T→L, L, or T. In 2011, due to futility the L arm was closed and is not included in this analysis. The primary end point is disease-free survival (DFS). Secondary objectives include treatment comparisons with respect to overall survival (OS), time to recurrence (TTR), time to distant recurrence (TDR), cardiac and overall safety and tolerability. Primary analysis results of the study were published in JCO 2015 34:1034-1042. This updated analysis occurs at a 6.9 yrs median follow up (MFU). Results: All patients have reached 5-years of follow-up. 705 DFS events for L+T vs T have been observed. HR for DFS was 0.86 (95% CI, 0.74-1.00; 6-yr DFS%=85% vs 82%) for L+T vs T and 0.93 (95% CI, 0.81-1.08; 6-yr DFS%=84% vs 82%) for T→L vs. T. The 6-year OS was 93%, 92%, and 91% for L+T, T→L, and T, respectively. HR for OS was 0.86 (95% CI, 0.70-1.06) for L+T vs. T and 0.88 (95% CI, 0.71-1.08) for T→L vs. T. DFS differences for L+T vs. T were slightly higher for the hormone-receptor(ER)-negative [HR 0.80 (95% CI, 0.64-1.00; 6-yr DFS%=84% vs. 80%)] and the sequential chemotherapy [HR 0.83 (95% CI, 0.69-1.00; 6-yr DFS%=83% vs.79%)] subgroups. There were no differences in sites of first DFS events according to treatment arm for CNS, loco-regional, or distant recurrences. There were more AEs related to study treatment (L+T 93% vs T 64%). The incidence of primary cardiac end points was low: 1% for L+T, 0.5% for T→L and 0.9% for T. Conclusions: The HRs for this updated analysis are similar to those from the Primary Analysis and the event rate remains lower than anticipated (705 vs 850 planned). Cardiac toxicity remains low. This analysis suggests that HER2+/ER- tumors may have a different biology than HER2+/ER+ and may benefit more from dual HER2 blockade. Long-term follow up continues. Clinical trial information: NCT00490139.
Noninvasive Cardiac Diagnosis
Authors: Alfred F. Parisi, Donald E. Tow, W. Robert Felix, Arthur A. Sasahara
Journal: New England Journal of Medicine (1977)

Assessment or Ventricular FunctionA number of noninvasive technics have been advocated as reflecting left ventricular performance. These methods include systolic-time intervals, echocardiography and imaging of the left ventricular chamber with radionuclides during systole and diastole.The determination of systolic-time intervals is noninvasive, extremely rapid and simple.106 , 107 A long preejection period with an accompanying short left ventricular ejection time is typically associated with a low ejection fraction and heart failure. In some circumstances, such as edematous states, the intervals have proved helpful in distinguishing the heart failure of cardiomyopathy from constrictive pericarditis.108 The latter condition is usually associated with normal . . .
Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations
Authors: Ron H.J. Mathijssen, Jaap Verweij, Maja J.A. de Jonge, Kees Nooter, Gerrit Stoter, Alex Sparreboom
Journal: Journal of Clinical Oncology (2002)

To evaluate relationships between various body-size measures and irinotecan (CPT-11) clearance and metabolism in cancer patients, and to provide future dosing recommendations for this agent.Pharmacokinetic data were obtained from 82 adult patients (50 men, 32 women; median age, 54 years) receiving CPT-11 as a 90-minute intravenous infusion (dose range, 175 to 350 mg/m(2)). In each patient, plasma samples were collected at timed intervals in the first administration of a 3-week schedule, and CPT-11 and its metabolite, SN-38, were measured by a liquid chromatographic assay.The mean (+/- SD) CPT-11 clearance was 33.6 +/- 10.8 L/h, with an interindividual variability (IIV) of 32.1%. When clearance was adjusted for body-surface area (BSA), the IIV was similar (34.0%). In addition, in a multiple linear regression analysis, none of the studied measures (BSA, lean body mass, [adjusted] ideal body weight, and body mass index) was a significant covariate (P >.13; r(2) <.014) in our population. Similarly, BSA did not significantly contribute to variability in the relative extent of conversion to SN-38 (P =.26).BSA is not a predictor of CPT-11 clearance or SN-38 pharmacokinetics and does not contribute to reducing kinetic variability. These findings provide a rationale for the conduct of a comparative phase III study between BSA-based dosing and flat or fixed dosing of CPT-11.
Scientific Session
Authors: Paul Lichter, William Coles, Richard Forster, Wayne Fung, Morton Goldberg, David Guyton, Robert Hepler, Charles Phelps, Andrea Tongue, Byron Demorest, Harold Stein, Toronto Ontario, Harold Dilcqssion, Bernard Stein, Onta Slatt, Louis Rio, Atlanta Wilson, Jack Hartstein, St Louis, Paul Honan, J Mcculloch, John Baker, Edward Raab, New York, Stanley Truhlsen, Stephen Obstbaum, Extracapsular Cataract, David Moderator, William Tasman, Arnall Patz
Journal: Ophthalmology (1984)
Drinking Less Alcohol Improves Heart Function in People with Alcohol-Related Heart Failure
Journal: Annals of Internal Medicine (2002)

Summaries for Patients5 February 2002Drinking Less Alcohol Improves Heart Function in People with Alcohol-Related Heart FailureSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-3-200202050-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Drinking alcohol heavily for several years can weaken the muscle walls of the heart. Weakened muscles then stretch, which enlarges the heart. A large, weakened heart cannot pump blood through the body normally. Symptoms such as fatigue, shortness of breath, and leg swelling result. Doctors call this serious disorder alcohol-related heart failure (alcoholic cardiomyopathy). Treatment with drugs can help symptoms, but heart transplant surgery is the only way for some people to improve their chances of living longer. Most doctors believe that people with alcoholic cardiomyopathy should avoid ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “The Effect of Controlled Drinking in Alcoholic Cardiomyopathy.” It is in the 5 February 2002 issue of Annals of Internal Medicine (volume 136, pages 192-200). The authors are JM Nicolás, J Fernández-Solà, R Estruch, JC Paré, E Sacanella, A Urbano-Márquez, and E Rubin.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Effect of Controlled Drinking in Alcoholic Cardiomyopathy Josep María Nicolás , Joaquim Fernández-Solà , Ramon Estruch , Joan Carles Paré , Emilio Sacanella , Alvaro Urbano-Márquez , and Emanuel Rubin Metrics 5 February 2002Volume 136, Issue 3Page: I-20KeywordsAddictionAlcoholicsAlcoholismAlcoholsCardiomyopathiesHeartHeart failureMusclesMyocardiumWine ePublished: 5 February 2002 Issue Published: 5 February 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
SMALL HOSPITALS
Authors: EDWARD F. STEVENS
Journal: JAMA (1925)

The highest medical and surgical efficiency may be attained only in hospitals of sufficient size to afford complete diagnostic, therapeutic and operating facilities; nevertheless there are and always will be smaller units for the care of the sick in localities where larger ones cannot be maintained. To meet this demand for the small surgical and medical units, this article is written. I have often met conditions such as the following: A wealthy person, feeling his obligation to a community and believing that a hospital would be the kindest expression of gratitude, leaves in his will his beautiful estate to a board of trustees, directing them to develop and maintain the estate as a public hospital. The board, anxious to carry out the wishes of their late friend and neighbor, choose an architect (let it be hoped), and he is given the problem of making this beautiful home into a well
Abstract 17436: Ten-year Clinical Outcomes After the First Sirolimus-eluting Stent Implantation: Impact of In-stent Restenosis Lesion
Authors: Katsuya Miura, Kazushige Kadota, Masanobu Ohya, Takenobu Shimada, Hidewo Amano, Yu Izawa, Yusuke Hyodo, Suguru Otsuru, Daiji Hasegawa, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto, Kazuaki Mitsudo
Journal: Circulation (2015)

Background: Little is known about the clinical follow-up after sirolimus-eluting stent (SES) implantation and about the effect of SES implantation in in-stent restenosis (ISR) lesion more than five years. We aimed to compare clinical outcomes up to 10 years after SES implantation in de novo lesion and ISR lesion. Methods: A series of 392 patients underwent the first SES implantation between November 2002 and December 2004, whose clinical outcomes were investigated. There were 253 patients for de novo lesion and 139 patients for ISR lesion. We evaluated the outcomes from the SES implantation to five years and beyond five years. Clinical information was obtained either from a review of the hospital records or by telephone interviews with the patients, family members, or primary care physicians. Results: Mean follow up period was 10.0 years. Cumulative incidence of major cardiac events (MACE) and target-lesion revascularization in ISR group were significantly higher than that in de novo group through 10 years (56.1% vs. 38.7%; p = 0.01, and 41.3% vs. 20.6%; p = 0.004, respectively) and the difference of the MACE and TLR rate in two groups increased in this period. Cumulative incidence of myocardial infarction (MI) and stent thrombosis (ST) between 2 groups were not significantly different (13.0% vs. 7.9%; p = 0.1, and 5.0% vs. 2.4%; p = 0.15, respectively). Conclusion: The incidence of MACE and TLR after the SES implantation in ISR lesion was significantly higher than that in de novo lesion and the difference of the TLR rate between in two lesions became more clear through 10 years, although the incidence of MI and ST had no significant difference in 2 groups.
The gastric mucosa in anaemia in Punjabis: Part II In megaloblastic anaemia
Journal: Gut (1966)

Part II In megaloblastic anaemiaEDITORIAL SYNOPSIS There is a relatively high incidence of atrophic gastritis in patients in the Punjab with megaloblastic anaemia.No correlation was found with age, degree of anaemia, steatorrhoea, iron deficiency, or response to vitamin B12 and folic acid.Nutritional deficiency, secondary to inadequate diet or conditioned by structural or functional disease of the small intestine, is the chief cause of the megaloblastic anaemias seen in the Punjab.It was therefore decided to examine the gastric mucosa of patients with megaloblastic anaemia (excluding that associated with pregnancy or the puerperium) in order to establish the incidence of atrophic gastritis in these cases, and to see if gastric atrophy, without marked cellular infiltration, occurred in this type of anaemia.
The Conquest of Life.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal